Portal de Periódicos da CAPES

Switching between TNFα antagonists in rheumatoid arthritis: personal experience and review of the literature

2011; PAGEPress (Italy); Volume: 61; Issue: 2 Linguagem: Inglês

10.4081/reumatismo.2009.107

2240-2683

Rossana Scrivo, Fabrizio Conti, Francesca Romana Spinelli, Simona Truglia, L. Magrini, Manuela Di Franco, Fulvia Ceccarelli, Guido Valesini,

Autoimmune and Inflammatory Disorders Research

The treatment of rheumatoid arthritis (RA) has evolved over the past decade with the introduction of anti-tumor necrosis factor (TNF) α agents, which allowed remarkable advances in controlling signs and symptoms of inflammation and in slowing joint destruction (1-3). However, some patients do not respond or show suboptimal response to the currently available anti- TNFα agents (infliximab, etanercept, and adalimumab) used either as monotherapy or in combination with methotrexate. Furthermore, patients who respond initially may lose efficacy over time (4) or develop adverse events.